The success of semaglutide has also intensified the pharmaceutical race other companies are developing their own GLP-1 approaches (for instance, Eli Lillys oral non-peptide GLP-1 agonist orforglipron is in late-stage trials, expected to file for FDA approval in 2026)
Development 136 , 40114020 (2009)
Compliance Notice All information on this page is provided strictly for educational and research purposes
Ideal candidates include those with treatment-resistant depression, individuals needing quick relief from severe symptoms, or those looking for a non-oral, integrative mental health option
Store sealed and dry, away from heat and light, following laboratory SOPs
[PMID: 21505960] PubMed record related to this compound for laboratory literature review